Page 10 - CIBEREHD2016-ENG

Significant Activities
Projects
NATIONAL
Financing agency: Instituto de Salud Carlos III
Understanding obesity (Ob), metabolic syndrome (MetS), type 2 diabetes (T2DM) and fatty liver disease (FL): a multidisciplinary approach (PIE14/00031).
Implementation of a tool based on ultra-sequencing for determining sub-genotypes of hepatitis C virus: optimisation of the treatment (PI14/01349).
Virological and immunological factors connected with anti-viral treatment and recurrence of hepatitis C after liver transplantation (PI13/00155).
Characterisation of microRNAs in pancreas cancer: from new biomarkers to therapeutic targets (PI13/02192).
Implication of activity of the extracellular matrix in the appearance of evolutionary complications in Crohn’s disease and in the development of new therapeutic proposals (PI12/0621).
Prospective clinical assessment of the genetic-immune/ inflammatory profile in the treatment of hepatocellular carcinoma with sorafenib to predict tolerance and survival. (PI15/00145).
Safety and clinical efficacy of intralesional administration of dendritic cells in patients with refractory Crohn’s disease.
Impact on the treatment of new antiviral agents in the natural history of cirrhosis by the hepatitis c virus. Identification of the factors predicting no response. Part A: Impact of the treatment with the new direct-acting antiviral agents on the natural history of advanced chronic liver disease (cirrhosis) and pathogenic mechanisms.
Impact on the treatment of new antiviral agents in the natural history of cirrhosis by the hepatitis c virus. Identification of the factors predicting no response. Part B: optimisation of the direct antiviral treatment of chronic Hepatitis C in clinical practice and identification of the factors associated with the lack of response.
State sub-programme on training contracts Río Hortega granted by the ISCIII (CM15/00050). Safety and clinical efficacy of intralesional administration of tolerogenic dendritic cells in patients with refractory Crohn’s disease (PI13/01585).
Financing agency: Ministry of the Economy and Competitiveness
Development of a kit for early diagnosis of colorectal cancer – Detection in plasma (miRNAs) (RTC-2015- 3850-1).
Other financing agencies:
Fundació la Marató on TV3 television station: “Anàlisi per biología de sistemes de la tolerància immunitària en trasplantament d’òrgans.” (122130/31/32).
AECC project
Transfer
One of the CIBER’s main aims is the transfer of the knowledge generated by its researchers, so that its research results can be developed in protocols, services and products for improving clinical practice and people’s quality of life. To this end the CIBER Technology Transfer department acts as a liaison between our researchers and companies, private institutions, public research centres and other innovation agents to make cooperation with them more effective and ensure that the results of research are actually applied. Work is done in several lines in order to achieve this aim:
• Continuous contact with our researchers to monitor their results and train them in management of innovation.
1203